PGR decision: Jul. 28, 2020
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
Final Written Decision
|
|
PGR2019-00026
|
03/01/2019
|
07/30/2019
|
Grunenthal GmbH
|
9,931,352
|
Antecip Bioventures
|
All Claims Unpatentable
|
|
PGR2019-00027
|
03/01/2019
|
07/30/2019
|
Grunenthal GmbH
|
10,039,774
|
Antecip Bioventures
|
All Claims Unpatentable
|
|
PGR2019-00028
|
01/03/2019
|
08/20/2019
|
Grunenthal GmbH
|
10,052,338
|
Antecip Bioventures
|
All Claims Unpatentable
|
US 9,931,352 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating hyperalgesia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from hyperalgesia associated with complex regional pain syndrome.
17. A method of treating edema associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from edema associated with complex regional pain syndrome.
US 10,039,774 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating changes in skin blood flow associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from changes in skin blood flow associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
16. A method of treating abnormal sudomotor activity associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from abnormal sudomotor activity associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
US 10,052,338 (ANTECIP BIOVENTURES II LLC): Non-OB
1. A method of treating allodynia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from allodynia associated with complex regional pain syndrome.
17. A method of treating autonomic motor change associated with complex regional pain syndrome (CRPS), comprising administering neridronic acid in a salt form or an acid form to a human being suffering from autonomic motor change associated with CRPS.
Leave a Reply